← Leaderboards
Jeffrey L. Dupree
Va Veterans Administration Hospital
$1,560,537
Attributed
$2,381,032
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $628.7K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,381,032 · 5
VA$0 · 3
By mechanism
R01$1,230,742 · 1
R21$853,532 · 2
R03$296,758 · 2
I01$0 · 2
IS1$0 · 1
Top collaborators
- Lizhen Chen2 shared
- Xianlin Han2 shared
Others in their field
Top investigators on “Myelin”
- James J Lah · Emory University$35,158,235
- Stephen Arthur Back · Oregon Health & Science University$23,494,618
- Vijay K Kuchroo · Brigham And Women'S Hospital$22,841,024
- Jeff W Lichtman · Washington University$21,489,807
- Bruce D Trapp · Cleveland Clinic Lerner Com-Cwru$21,079,355
- Brian J Popko · Northwestern University$20,097,136
Research focus
MyelinNeuronsPlayCellsMultiple SclerosisPathologyDemyelinationsAlzheimer&AposBaseCell TypeAxonSitePathologicMotorEventSensoryMediatingCognitive DeficitsStructureRepairedDemyelinating DiseasesImpaired CognitionExperimental Autoimmune EncephalomyelitisInflammatory
Grant awards (21)
The role of sulfatide in the development of tauopathy in the context of ADRD$602,040
R01 · FY2025 · AG
The role of sulfatide in the development of tauopathy in the context of ADRD$628,702
R01 · FY2024 · AG
Attenuating microglial-dependent axonal pathology in EAE$0
I01 · FY2024 · VA · contact PI
The ShEEP request for a ZEISS Laser Scanning Confocal Microscope 980 with Airyscan 2$0
IS1 · FY2024 · VA · contact PI
Attenuating microglial-dependent axonal pathology in EAE$0
I01 · FY2023 · VA · contact PI
The role of sulfatide in myelin stability$232,875
R21 · FY2022 · NS · contact PI
Attenuating microglial-dependent axonal pathology in EAE$0
I01 · FY2022 · VA · contact PI
The role of sulfatide in myelin stability$194,063
R21 · FY2021 · NS · contact PI
Attenuating microglial-dependent axonal pathology in EAE$0
I01 · FY2021 · VA · contact PI
Attenuating microglial-dependent axonal pathology in EAE$0
I01 · FY2020 · VA · contact PI
Microglial neurofascin: a novel mediator of microglia/axon initial segment interactions?$232,844
R21 · FY2019 · NS · contact PI
Microglial neurofascin: a novel mediator of microglia/axon initial segment interactions?$193,750
R21 · FY2018 · NS · contact PI
Identification and Repair of Novel Axonal Pathology in Demyelinating Disease$0
I01 · FY2018 · VA · contact PI
Identification and Repair of Novel Axonal Pathology in Demyelinating Disease$0
I01 · FY2017 · VA · contact PI
Identification and Repair of Novel Axonal Pathology in Demyelinating Disease$0
I01 · FY2016 · VA · contact PI
The Potential of Didox as an Oral Therapy for Multiple Sclerosis$0
I01 · FY2016 · VA · contact PI
Identification and Repair of Novel Axonal Pathology in Demyelinating Disease$0
I01 · FY2015 · VA · contact PI
Generation of a floxed CST mouse$73,255
R03 · FY2011 · NS · contact PI
Generation of a floxed CST mouse$74,750
R03 · FY2010 · NS · contact PI
Determining the mechanisms that regulate neurofascin155 distribution in myelin$74,003
R03 · FY2010 · NS · contact PI
Determining the mechanisms that regulate neurofascin155 distribution in myelin$74,750
R03 · FY2009 · NS · contact PI